Transcriptomics

Dataset Information

0

Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study


ABSTRACT: Neoadjuvant immune checkpoint blockade (ICB) has shown unprecedented activity in mismatch repair deficient (MMRd) colorectal cancers, but its effectiveness in MMRd endometrial cancer (EC) remains unknown. In this investigator-driven, phase I, feasibility study (NCT04262089), 10 women with MMRd EC of any grade, planned for primary surgery, received two cycles of neoadjuvant pembrolizumab (200 mg IV) every three weeks. All patients completed treatment without severe toxicity. A partial radiologic response was observed in 3/10 patients, 5/10 patients had stable disease and 2/10 patients were non-evaluable on Magnetic Resonance Imaging (MRI). Pathologic response was observed in 5/10 patients, with 2 patients showing a major pathologic response. No patient achieved a complete pathologic response. At median duration of follow-up of 22.5 months, two non-responders experienced disease recurrence. Monoclonal T cell expansion significantly correlated with treatment response. Tumour-draining lymph nodes displayed clonal overlap with intra-tumoural T cell expansion. All pre-specified endpoints were reached. Neoadjuvant ICB with pembrolizumab proved safe and induced pathologic, radiologic, and immunologic responses in MMRd EC, warranting further exploration of extended neoadjuvant treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE268903 | GEO | 2024/07/19

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-10-07 | GSE212217 | GEO
2024-01-01 | GSE202361 | GEO
2024-09-24 | GSE264695 | GEO
2024-01-09 | PXD040399 | Pride
2012-05-11 | E-GEOD-37946 | biostudies-arrayexpress
2021-08-31 | GSE181815 | GEO
2011-05-11 | E-GEOD-25065 | biostudies-arrayexpress
2011-05-11 | E-GEOD-25055 | biostudies-arrayexpress
2018-12-05 | GSE121810 | GEO
2015-01-21 | E-GEOD-48073 | biostudies-arrayexpress